Piper Sandler Reaffirms Tango Therapeutics’ Stock Overweight Rating Amid Drug Pipeline Developments
Tango Therapeutics Stock : Analyst Confidence Stays Strong Piper Sandler has reaffirmed its Overweight rating for Tango Therapeutics Inc stock(NASDAQ: TNGX). The price target remains
